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Tirapazamine-induced DNA damage measured using the comet assay
correlates with cytotoxicity towards hypoxic tumour cells in vitro
BG Siim, PL van Zijl and JM Brown
Department ofRadiation Oncology, Stanford University School ofMedicine, Stanford, CA 94305-5468, USA.
Summary Tirapazamine (SR 4233), a bioreductive drug selectively toxic towards hypoxic cells, is presently in
phase II clinical trials. Since it would not be expected that all tumours would respond equally to the drug, we
are exploring ways of predicting the response of individual tumours. In this study we have tested whether the
comet assay, which measures DNA damage in individual cells, can provide a simple, surrogate end point for
cell killing by tirapazamine. We examined the relationship between the cytotoxicity of tirapazamine under
hypoxic conditions and tirapazamine-induced DNA strand breaks in murine (SCCVII, EMT6, RIF-1) and
human (HT1080, A549, HT29) tumour cell lines. These results were compared with the relationship between
tirapazamine cytotoxicity and another measure of the ability of cells to metabolise tirapazamine; high-
performance liquid chromatography (HPLC) analysis of tirapazamine loss or formation of the two electron
reduction product SR 4317. The correlation between the hypoxic cytotoxic potency of tirapazamine and DNA
damage was highly significant (r=0.905, P=0.013). A similar correlation was observed for hypoxic potency
and tirapazamine loss (r=0.812, P=0.050), while the correlation between hypoxic potency and SR 4317
formation was not significant (r=0.634, P=0.171). The hypoxic cytotoxicity of tirapazamine in vitro can
therefore be predicted by measuring tirapazamine-induced DNA damage using the comet assay. This approach
holds promise for predicting the response of individual tumours to tirapazamine in the clinic.
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Many human tumours contain a significant subpopulation of
cells at low oxygen tensions (H6ckel et al., 1991; Mueller-
Kleiser et al., 1991; Vaupel et al., 1991). These hypoxic cells,
which can present a problem in the radiotherapy of solid
tumours (Bush et al., 1978; Gatenby et al., 1988; Hockel et
al., 1993), are probably also resistant to many chemother-
apeutic agents (Tannock, 1978; Hughes et al., 1989; Wilson
and Denny, 1992). It has recently been proposed that with
the use of bioreductive drugs, which are selectively activated
to a cytotoxic species under hypoxic conditions, it may be
possible to exploit hypoxic tumour cells so that their presence
in solid tumours is an advantage rather than a disadvantage
(Brown and Koong, 1991; Denny and Wilson, 1993; Brown
and Giaccia, 1994). This promising approach is about to be
tested in the clinic with two new bioreductive drugs in, or
about to enter, clinical trials; the benzotriazine di-N-oxide
tirapazamine (SR 4233, WIN 59075) (Brown, 1993; Doherty
et al., 1994) and the dual-function alkylating nitroimidazole
RB 6145 (or the less emetic R isomer PD 144872) (Cole et al.,
1992; Sebolt-Leopold et al., 1993).
In the clinic it is expected that only patients with tumours
containing a significant proportion of hypoxic cells would
respond to a bioreductive drug that is selectively toxic
towards hypoxic cells. The response of a tumour to any such
bioreductive drug will depend both on the level of activity of
the reductase(s) that activate the drug to a cytotoxic species,
and the level of tumour hypoxia. Recent studies have shown
that reductase activity can vary substantially between
different human tumour cell lines (Plumb et al., 1994;
Robertson et al., 1994), and measurements made using
oxygen electrodes show large variations in oxygen tensions
between tumours (Vaupel et al., 1991). It would therefore be
highly desirable to be able to predict the response of
individual tumours to a bioreductive drug so that patients
unlikely to benefit from the drug would not be treated with it,
and further, the power of a clinical trial of the drug to
produce a significant response would be improved.
Tirapazamine exhibits high hypoxia-selective cytotoxicity
in the order of 50 to 200-fold in most rodent and human cell
lines (Zeman et al., 1986, 1988; Stratford and Stephens,
1989). Tirapazamine also kills hypoxic cells in transplanted
tumours in mice (Zeman et al., 1988; Kim and Brown, 1994;
Durand, 1994) and has been shown to potentiate the effects
of modalities that are more toxic towards aerobic tumour
cells. In particular, a large potentiation of tumour cell kill has
been observed with fractionated radiation (Brown and
Lemmon, 1990, 1991) and with some chemotherapeutic
agents, particularly cisplatin (Dorie and Brown, 1993).
Tirapazamine is currently in phase II clinical trials in
combination with radiation and with cisplatin.
The metabolic activation of tirapazamine involves one
electron reduction to a free radical species which, in the
presence of oxygen, is back-oxidised to regenerate the parent
drug with concomitant production of superoxide. Under
hypoxic conditions the tirapazamine radical can abstract a
hydrogen atom from DNA and produce a DNA strand break
(Figure 1). The hypoxic cytotoxicity of tirapazamine is due to
the formation of DNA double-strand breaks (dsbs) and
resulting chromosome aberrations (Biedermann et al., 1991;
Wang et al., 1992). Although it would be desirable to measure
the cytotoxic lesion directly, it is probable that the low yield of
dsbs in hypoxic cells treated with tirapazamine (Zeman and
Brown, 1989; Olive, 1995a) would preclude measurement of
dsbs using clinically achievable drug doses. We propose that
the alkaline comet assay, which measures DNA single-strand
breaks (ssbs) in individual cells (Olive et al., 1990), may be
used as a predictive assay for tumour response to
tirapazamine. For this to hold, the ratio of DNA ssbs to
dsbs would have to be constant across cell lines and the
number of initial dsbs (and hence ssbs) predictive of cell kill.
DNA damage measured using the comet assay should be a
function of both the level of tumour hypoxia and reductase
activity. In the present study we have assessed the relationship
between tirapazamine-induced DNA damage and cytotoxicity
in a number of murine (SCCVII, EMT6, RIF-1) and human
(HT1080, A549, HT29) tumour cell lines treated with
tirapazamine under hypoxic conditions. We have compared
this with the correlation between hypoxic cytotoxicity and
another measure of cells' ability to metabolise tirapazamine;
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high-performance liquid chromatography (HPLC) analysis of
tirapazamine loss and formation ofthe two electron reduction
product SR 4317 (Figure 1).
Materials and methods
Cells and drugs
Details of the derivation of the SCCVII (Hirst et al., 1983),
EMT6 (Rockwell et al., 1972) and RIF-1 (Twentyman et al.,
1980) cell lines have been described previously. HT1080 and
A549 cells were obtained from the American Type Culture
Collection. HT29 cells were obtained from Dr RM Suther-
land (SRI International, Menlo Park, CA, USA). Cells were
cultured in Alpha MEM (HT1080, A549), McCoys 5A
(HT29) or Waymouth's (SCCVII, EMT6, RIF-1) media
supplemented with 10% (HT1080, A549, HT29) or 15% fetal
bovine serum (FBS) (SCCVII, EMT6, RIF-1) plus penicillin
(100 IU ml-') and streptomycin (100 ig ml-'). Tirapazamine
was kindly supplied by Sterling Winthrop and SR 4317 and
SR 4430 by SRI International.
Hypoxic drug exposures
Hypoxic drug exposures were performed in double side-
armed glass flasks (Wheaton Jacketed Reaction Vessels) at
37°C with continuous stirring using glass-coated magnetic stir
bars. Tirapazamine solutions (9 ml), in alpha minimal
essential medium (MEM) containing 10% FBS and
antibiotics as above, at 1.25 times the final required drug
concentration were equilibrated with humidified gas (nitro-
gen-5% carbon dioxide) for 60 min before sampling of 1 ml
for HPLC analysis. Drug exposure was initiated by addition
of cells (2 ml at 2.5 x 106 cells ml-' equilibrated under the
same conditions). Samples of 0.5 ml (2.5 x 105 cells) were
taken after 5 min drug exposure and added to ice-cold
phosphate-buffered saline (PBS) to give a final density of
2 x 104 cells ml-' for determination of DNA damage using
the comet assay. After 60 min drug exposure, samples were
taken to determine cytotoxicity and for HPLC analysis of
tirapazamine and SR 4317 concentrations. Colony formation
was assessed after incubation at 37°C for 8 (EMT6), 9
(SCCVII), 10 (HT1080), 12 (RIF-1, A549) or 14 days (HT29)
by staining with 0.25% crystal violet in 95% ethanol and
counting colonies containing >50 cells.
Comet assay
The alkaline comet assay was performed as described
previously by Olive and coworkers (Olive and Durand,
1992; Olive et al., 1992). Briefly, 0.5 ml of cell suspension
(2 x 104 cells ml-' in cold PBS) was added to 1.5 ml of a 1%
solution of low gelling temperature agarose (Sigma Type
VII), mixed and pipetted onto a microscope slide on a cold
block. The slides were placed in alkaline lysis solution
(30 mm sodium hydroxide, 1 M sodium chloride, 0.1% N-
lauroylsarcosine) for 60 min, then washed for 3 x 20 min in
alkaline rinse solution (30 mM sodium hydroxide, 2 mM
EDTA), followed by electrophoresis at 0.4 V cm-' for
25 min in a fresh solution of 30 mm sodium hydroxide,
2 mM EDTA. Slides were rinsed with distilled water for
15 min, then stained with propidium iodide (2.5 Mg ml-') for
15 min.
The neutral comet assay was performed as described by
Olive (1995a). Slides prepared as above were placed in lysis
solution (0.5% sodium dodecyl sulphate, 30 mM EDTA, pH
8.3) at 50°C for 4 h. Some slides were incubated overnight at
37°C with 0.5 mg ml-' proteinase K. After lysis slides were
washed for at least 6 h in rinse buffer (90 mM tris, 90 mM
boric acid, 2 mM EDTA, pH 8.5), followed by electrophoresis
at 0.6 V cm-' for 25 min in fresh rinse buffer.
All slides were analysed within 48 h. The DNA from
individual cells was visualised using a 20 x objective with a
Nikon Optiphot microscope attached to an Ikegami 4612
CCD camera and fluorescence image analysis system
described by Olive et al. (1990). DNA damage was
quantitated as the tail moment, the product of percentage
of DNA in the tail and the mean tail length. A total of 150
comets were analysed per sample.
HPLC
Metabolism of tirapazamine was assessed from HPLC
analysis of samples of extracellular medium for parent drug
and the two electron reduction product SR 4317. This
provides an accurate assessment ofcellular metabolism as the
ratios of intracellular to extracellular concentrations for
tirapazamine and SR 4317 are low (1.5-2 and 4-5
respectively in A549 cell cultures; PL van Zijl, unpublished
data), and under the exposure conditions (5 x 105 cells ml-1)
the extracellular volume is approximately 103-fold greater
than the intracellular volume, so the vast majority ofthe drug
and reduction product will be in the extracellular compart-
ment. The HPLC system consisted of a Waters pump (model
6000A), a WISP autosampler (model 712), a Waters Nova
Pak-phenyl column (3.9 x 150 mm) and a Waters UV-visible
detector (model 490E). The mobile phase was 22.5%
methanol in water at a flow rate of 1.2 ml min-'. Under
these conditions tirapazamine, SR 4317 and SR 4330 had
retention times of 3.7, 8.9 and 7.0 min respectively.
Quantitation was based on peak areas using absorbance at
269 nm for tirapazamine and 238 nm for SR 4317 and SR
4330.
Results
The cytotoxicity of tirapazamine towards three human
(HT1080, A549, HT29) and three murine (SCCVII, RIF-1,
EMT6) tumour cell lines was assessed under hypoxic
conditions and correlated with three measures of drug
metabolism determined in the same experiments: production
of tirapazamine-induced DNA strand breaks, loss of
tirapazamine and formation of SR 4317.
HPLC analysis ofmetabolism
Tirapazamine solutions were equilibrated with nitrogen-5%
carbon dioxide for 60 min before initiation of drug exposure
by addition of cells equilibrated under identical conditions.
Before mixing, samples were taken for HPLC analysis to
check for evaporative loss of water from the drug solutions.
There was consistent, reproducible metabolism of tirapaza-
mine in media gassed under hypoxic conditions, as indicated
by detection of the two-electron reduction product SR 4317.
For an initial drug concentration of 50 gIM, approximately
0.5 gM SR 4317 was detected following 60 min gassing under
hypoxic conditions, with a 2-fold higher concentration
detected after 120 min (Table I). This metabolism in the
absence of cells was via the oxygen-sensitive one-electron
reduction product as there was complete inhibition of
Table I Chemical reduction of tirapazamine (50 tiM) under hypoxic
conditions
SR 4317 (MM)a
Solvent 60 min 120 min
Alpha MEM + 10% FBS 0.45±0.04b 1.00±0.07b
Alpha MEM no FBS 0.44±+0.13b 1.05±0.41b
PBS 0.02± 0.01 0.03+ 0.01
PBS+10% FBS 0.13±0.01 0.21+0.02
PBS+ 50 mg 1-1 ascorbate 0.24+0.02 0.46+ 0.06
PBS + 100 mg 1-1 cysteine 0.71 i0.23 0.90+0.25
PBS+ 10% FBS+50m 0.24+0.08 0.51±+0.19
ascorbate + 100 mg 1-
cysteine
PBS+5 mM GSH 0.47+0.13 0.70+0.16
aValues are means ± s.e.m. for three independent experiments.
bValues are ranges for two independent experiments.DNA damage by tirapazamine
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metabolism when tirapazamine was gassed under aerobic
conditions. Metabolism was also inhibited in PBS, although
addition of FBS, cysteine or ascorbate to PBS at the
concentrations present in a-MEM each resulted in some
metabolism of tirapazamine, which increased with time of
hypoxic gassing (Table I). It thus appears that there are a
number of reducing agents present in a-MEM that can
chemically reduce tirapazamine under hypoxic conditions.
Rates of cellular metabolism of tirapazamine were therefore
corrected for this chemical reduction. Reduced glutathione, a
reducing agent present in high concentrations in most cells,
can also reduce tirapazamine under hypoxic conditions
(Table I).
The rate of metabolism of tirapazamine in hypoxic
cultures, as measured by HPLC analysis of tirapazamine
loss, or formation of SR 4317 in the extracellular media,
increased linearly with tirapazamine concentration in each of
the cell lines investigated (Figure 2a,b). The rate of
tirapazamine loss decreased in the order
EMT6>SCCVII>RIF-1 >HT29>A549>HT1080 (Figure
2a). Rates of formation of SR 4317 followed a similar
pattern; EMT6>SCCVII > RIF-1 A549 >HT29 >HT1080
(Figure 2b). The amount of SR 4317 detected in hypoxic
A549 cultures was high relative to the amount of
tirapazamine metabolised. In A549 cells about 70% of the
tirapazamine metabolised was detected as SR 4317, compared
with about 45% for the other cell lines. No SR 4330, the four
electron reduction product of tirapazamine, was detected in
any of the samples.
DNA damage (comet assay)
The neutral comet assay was used to measure DNA dsbs in
hypoxic SCCVII cells treated with tirapazamine for 60 min.
For a tirapazamine concentration of 20 gM, which produces
approximately 2.5 logs of cell killing after 60 min drug
exposure, there was essentially no increase in DNA damage
above control levels either with or without proteinase K
(Figure 3). In the absence of proteinase K no damage was
detected even at drug concentrations of up to 200 Mm. In
contrast, incubation with proteinase K provided a linear
increase in DNA damage with tirapazamine concentration.
Initial experiments with the alkaline comet assay con-
firmed that there was a linear relationship between DNA
damage (strand breaks) and radiation dose up to 20 Gy for
SCCVII and A549 cells (Figure 4). In hypoxic SCCVII cells
treated with 15 gM tirapazamine (a drug concentration that
gives approximately 2 logs of cell kill after 60 min exposure)
DNA damage increased linearly with time of drug exposure
at early times before appearing to saturate after about 10 min
exposure (Figure 5a). The apparent saturation of damage
appears to reflect the upper sensitivity limit for the comet
assay under the conditions described earlier. Comets from
highly damaged cells have very little DNA in the head of the
comet and consequently are not recognised by the image
analysis program. Tirapazamine-induced DNA damage was
therefore assessed in all further experiments after 5 min drug
exposure. However, recent experiments with hypoxic SCCVII
cells and lower tirapazamine concentrations have indicated
that DNA damage reaches an equilibrium after 10 min drug
exposure that is dependent on the drug concentration (data
not shown). The basis for this is currently under investiga-
tion. In hypoxic SCCVII cells DNA damage measured either
5 or 60 min after initiation ofdrug exposure showed a similar
relationship to cytotoxicity determined after 60 min (Figure
Sb).
As DNA damage was not normally distributed (Figure 6a-
d), we have used the median tail moment as being
representative of average damage. Tail moment was indepen-
dent of DNA content, calculated from total cellular fluores-
cence (Figure 6e and f), indicating there is no cell cycle
specificity ofDNAdamage. Ineachofthecelllinesinvestigated
DNA damage induced by tirapazamine under hypoxic
conditions increased linearly with drug concentration (Figure
6g), with the exception of the highest concentrations in the
human cell lines where damage appeared to saturate, although
cytotoxicity still increased (Figure 7). The murine cell lines all
had similar sensitivities to induction ofssbs by tirapazamine, as
did the human cell lines. For a given tirapazamine concentra-
tion there was about 2-fold greater DNAdamage in themurine
than in the human lines (Figure 6g).
Cytotoxicity
The cytotoxicity of tirapazamine towards hypoxic cell
cultures following a 60 min drug exposure was assessed by
DNA ssbs
+
DlNA dsbs
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2e- reduction
Tirapazamine radical
Cell death
SR 4317
Figure 1 Scheme showing metabolic activation of tirapazamine. One electron reduction gives a radical species that is back-oxidised
in the presence of oxygen. Under hypoxic conditions the radical can abstract a hydrogen atom from DNA to produce a strand
break and SR 4317. SR 4317 can also be formed by disproportionation of two tirapazamine radicals or directly from tirapazamine
by two electron reduction. Hypoxic cell death results from formation of DNA dsbs. This study compares the correlation between
DNA strand break production and hypoxic cytotoxicity with the correlation between loss of tirapazamine or formation of SR 4317
and cytotoxicity.
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tions (Figure 7). The murine tumour cell lines all had similar
sensitivities to cell killing by tirapazamine under hypoxic
conditions, and were 2- to 3-fold more sensitive than the
human cell lines.
Relationship between sensitivity to tirapazamine and DNA
damage
As DNA damage was linearly related to tirapazamine
concentration (Figure 6g), the sensitivity to ssb production
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was measured from the slope of the dose-response curves.
These values were plotted against hypoxic cytotoxic potency,
calculated as the reciprocal of the C1O value (drug
concentration required to reduce survival to 10%) obtained
by interpolation from Figure 7. There was a highly significant
correlation (r=0.905, P=0.013) between sensitivity to ssb
production and hypoxic potency (Figure 8a). The potency of
tirapazamine towards the human cell lines was 2- to 3-fold
lower than towards the murine lines, with tirapazamine
producing 2- to 3-fold less DNA damage in the human than
in the murine lines.
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Tirapazamine concentration (gM)
Figure 3 DNA damage (dsbs) measured using the neutral comet
assay after 60min exposure of hypoxic SCCVII cells to
tirapazamine. (0) No proteinase K; (0) overnight incubation
with proteinase K. The mean+s.e. for 150 comets is shown for
each dose.
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Figure 2 Rate ofmetabolism of tirapazamine in hypoxic cultures
as a function of initial drug concentration. (a) Tirapazamine loss.
(b) Formation of SR 4317. 0, SCCVII; *, RIF-1; V, EMT6; 0,
HT29; A, A549; O, HT1080 cells. Error bars represent s.e.m. for
three independent experiments and are smaller than the plotted
symbol where not shown.
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Figure 4 DNA damage measured using the alkaline comet assay
as a function of radiation dose in SCCVII (0) and A549 (A)
cells irradiated on ice. The mean+s.e. for 150 comets is shown for
each dose.
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Relationship between sensitivity to tirapazamine and
metabolism
First-order rate constants for loss of tirapazamine oi
formation of SR 4317 were calculated from the slopes ol
the plots in Figure 2 and plotted against hypoxic cytotoxic
potency (Figures 8b and c). There was a significani
correlation (r=0.812, P=0.050) between the rate constant4
for tirapazamine loss and hypoxic potency, with tirapazamint
being most potent against the SCCVII, RIF-1 and EMT6 cel
lines and being metabolised fastest in those lines (Figure 8b)
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Figure 5 (a) Time course for formation of DNA ssbs in hypoxic
SCCVII cells treated with 15 gM tirapazamine. (b) Relationship
between DNA damage (tail moment) measured after 5 (O) or 60
(0) min exposure of hypoxic SCCVII cells to tirapazamine, and
cell survival after 60min. The mean+ s.e. for 150 comets is shown
for each point.
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While the rate constants for SR 4317 formation increased
with potency (Figure 8c), the correlation was not significant
(r=0.634, P=0.171).
Discussion
s This study is the first step in determining whether the comet
e assay can be used to predict tumour response to
ll tirapazamine. Olive and colleagues have adapted the single-
cell gel electrophoresis method described by Ostling and
Johanson (1984) to video image analysis and reported many
applications for the comet assay, including the detection of
radiation-induced apoptosis (Olive et al., 1993b), DNA dsbs
(Olive et al., 1991), and hypoxia in murine tumours (Olive
and Durand, 1992; Olive, 1995a,b) and in human breast
tumours (Olive et al., 1993a). The mechanism of hypoxic
cytotoxicity of tirapazamine, by the formation of DNA dsbs
and resulting chromosome breaks, suggested to us that the
comet assay, which measures DNA strand breaks in
individual cells, may predict for cell killing by tirapazamine
under hypoxic conditions. While it would be preferable to
measure the cytotoxic lesion (DNA dsbs) directly, the low
yield of such lesions necessitates the use of supertoxic drug
doses (Figure 3), which would clearly preclude the use of
such an assay in clinical situations. The present study
demonstrates a good correlation between tirapazamine-
induced DNA ssbs and hypoxic cell killing by tirapazamine
in vitro, suggesting fulfillment of the requirement that the
ratio of DNA ssbs to dsbs would have to be constant across
cell lines, and the number of initial dsbs and ssbs predictive
of cell kill.
The observed 2 to 3-fold greater sensitivity of the murine
tumour cell lines to killing by tirapazamine under hypoxic
conditions compared with the human lines is consistent with
previously published data (Zeman et al., 1986; Biedermann et
al., 1991) and appears to underlie the lower hypoxic
cytotoxicity ratios (ratio of drug concentrations required to
give the same level of killing under aerobic and hypoxic
conditions) reported for tirapazamine in human than in
murine cell lines (Zeman et al., 1986). It should be recognised
that, although the hypoxic selective cytotoxicity of tirapaza-
mine is generally lower in human than murine cell lines, it is
still substantial, with hypoxic cytotoxicity ratios of around 50
being common (Zeman et al., 1986). Tirapazamine induced 2-
to 3-fold more DNA damage in the hypoxic murine cell lines
than in the human cell lines, indicating that the variation in
hypoxic sensitivity could be entirely accounted for by the
production of DNA strand breaks.
From the limited number of cell lines in the present study
it appears that the correlation between DNA damage and cell
survival could largely result from interspecies differences. The
similar DNA damage and sensitivity of each of the human
and each of the murine cell lines suggests that they must
possess similar levels of activity of the reductase(s) that
activates tirapazamine to a cytotoxic species. However, in the
clinic, wide variations in reductase activity, as has been
reported for human tumour cell lines (Plumb et al., 1994;
Robertson et al., 1994), and varying levels of hypoxia
(Vaupel et al., 1991), would be expected to result in large
differences in sensitivity to tirapazamine. It is of primary
importance that in this study, by measuring DNA damage, it
was possible to distinguish between cell lines with 2- to 3-fold
differences in sensitivity to killing by tirapazamine under
hypoxic conditions. Although we measured initial DNA
damage after 5 min drug exposure, when the effects of repair
should be minimal, and showed this to correlate with
cytotoxicity after 60 min, it appears that, at least for the
SCCVII cell line, DNA damage after 60 min also correlates
with cytotoxicity (Figure 5b). This augurs well for when this
approach is tested in vivo in animal models, or in the clinic,
as in these situations it will not be possible to measure initial
DNA damage.
In the present study high numbers of ssbs were produced
very rapidly in hypoxic cells treated with tirapazamine. A
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Figure 6 DNA damage (ssbs) as a function of tirapazamine concentration in hypoxic cultures after 5min drug exposure. (a-d)
Representative histograms for RIF-l cells treated with increasing doses oftirapazamine. (e, f) Representative plots for RIF-1 cells of
tail moment vs DNA content. Each symbol represents an individual cell. (g) 0, SCCVII; *, RIF-1; V, EMT6; 0, HT29; A, A549;
O, HT1080 cells. Error bars represent s.e.m. for three independent experiments and are smaller than the plotted symbol where not
shown.
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Figure 7 Sensitivity of hypoxic cultures to cell killing by
tirapazamine following a 60min drug exposure. *, SCCVII; *,
RIF-1; V, EMT6; 0, HT29; A, A549; O, HT1080 cells. Error
bars represent s.e.m. for three independent experiments and are
smaller than the plotted symbol where not shown.
median tail moment of approximately 13 was observed after
5 min exposure of hypoxic SCCVII cells to 15 gM
tirapazamine (Figures 5a, 6g), a drug concentration that
produces about two logs of cell kill after 60 min drug
exposure (Figure 7). In SCCVII cells irradiated on ice with
an equitoxic dose of y-rays [10 Gy, surviving fraction
(SF) = 3.55 x 10-2, 2.55 x 10-2 and 2.40 x 10-2 in three
independent experiments], a median tail moment of about
15 was observed (Figure 4). If the rate of DNA ssb induction
by tirapazamine is extrapolated from 5 min to 1 h, assuming
a linear time dependence, this would predict a median tail
moment of approximately 150 at an equitoxic drug dose to
10 Gy radiation. This calculation would seem to suggest that
tirapazamine induces approximately ten times more ssbs than
do equitoxic doses of y-rays. However, the number of strand
breaks in tirapazamine-treated cells at any given time will
depend on the rate of damage induction and the rate of
damage repair, whereas repair is largely inhibited in cells
irradiated on ice. Therefore it is not possible to make direct
comparisons of the amount of DNA damage, especially
initial DNA damage, in drug-treated and irradiated cells.
Similarly, it is difficult to deduce ratios of ssbs to dsbs as
these lesions will be repaired at different rates. However,
Olive (1995a) has reported a ratio of 10:1 ssbs/dsbs in anoxic
V79 spheroids treated with tirapazamine for 1 h, compared
with a ratio of 20:1 ssbs/dsbs for X-irradiation of aerobic
V79 cells. The present study confirms the finding of Olive
(1995a) that tirapazamine-induced dsbs in hypoxic cells are
protein associated. While protein-linked breaks are char-
acteristic of topoisomerase inhibitors, another explanation
could be that tirapazamine is causing the formation of
DNA-protein crosslinks as observed in cells irradiated under
hypoxic conditions (Zhang et al., 1995).
Cell lines deficient in repair of DNA dsbs have been
reported to be more sensitive to killing by tirapazamine
under hypoxia than predicted from their rates of drug
metabolism, suggesting that the ability to repair tirapaza-
mine-induced dsbs is an important determinant of sensitivity
to the drug (Biedermann et al., 1991). The excellent
correlation in the present study between tirapazamine-
induced DNA damage and hypoxic cytotoxicity for all of
the cell lines investigated suggests that there are no significant
differences in rates of repair of drug-induced DNA damage
between these cell lines.
It has been proposed that activation of tirapazamine by a
nuclear reductase produces a high local concentration of
tirapazamine radicals and multiple DNA strand breaks
similar to those produced by high linear energy transfer
(LET) radiation (Brown, 1993). Consistent with this is the
much lower sensitivity of the hypoxic cytotoxicity of
tirapazamine to inhibition by oxygen than that reported for
many other bioreductive drugs (Marshall and Rauth, 1988;
h %^ =A A A A-^ n
-r%However, in tnese two previous studies rates oI tormatlion
of SR 4317 were measured under non-physiological
conditions; Biedermann et al. (1991) used a supertoxic
tirapazamine concentration of 200 Mm, whereas Patterson
et al. (1995) measured rates of metabolism in cell lysates.
Formation of SR 4317 is a surrogate measure of
formation of the cytotoxic one electron reduction product
of tirapazamine. SR 4317 can be formed from the
tirapazamine radical by hydrogen abstraction from DNA,
or disproportionation of two radicals. Alternatively, SR
4317 can be formed directly from tirapazamine by two
electron reduction, as catalysed by DT diaphorase (Figure
1). The existence of detoxifying routes of formation of SR
4317 other than hvdrozen abstraction by the tiranazamine
radical could account for the poor correlation between SR
4317 formation and cytotoxicity in the present study.
0 10 20 30 40 50 60
Potency (1/C1o, mM-)
Figure 8 Relationship between the cytotox
tirapazamine under hypoxic conditions and (a), i
production; (b), rate constants for tirapazamin
constants for formation of SR 4317. 0, SCCVI]
EMT6; 0, HT29; A, A549; O, HT1080 cells.
Koch, 1993; Siim et al., 1994). It is therefc
only a small proportion of the total cellulai
tirapazamine may be responsible for cytoto.
the existence of nuclear reductases has nc
vocally proven, there is strong evidence fo
reduction of bifunctional nitroimidazoles cov;
DNA (Stratford et al., 1986; Moselen et
results in this study, where hypoxic cytoto
with tirapazamine loss, are consistent with a
nuclear to cytosolic reduction of tirapazamin
cell lines investigated.
Despite the significant correlation be
cytotoxicity and metabolic consumption
the correlation between formation of SR 4
was poor. It has previously been reported I
of tirapazamine under hypoxic conditiow
formation of SR 4317, correlates with hyp(
in vitro (Biedermann et al., 1991; Patterso
The observation of chemical reduction of tirapazamine
by reducing agents under hypoxic conditions is interesting.
Although, with an initial concentration of tirapazamine of
50 Mm, only 1% (0.5 gM) was detected as SR 4317 after
60 min gassing under hypoxia, this is a large proportion
of the SR 4317 (1-2 gM) detected after 60 min in hypoxic
human cell cultures at a density of 5 x 105 cells ml-I
treated with 50 gM tirapazamine. Ascorbate-catalysed
reduction of mitomycin C has been reported (Marshall
and Rauth, 1986) and ascorbate has also been reported to
reduce tirapazamine under both aerobic and hypoxic
conditions (Silva and O'Brien, 1993). Electronspin
resonance (ESR) spectroscopy, and measurement of one
electron redox cycling, indicated that the ascorbate-
catalysed reduction of tirapazamine was via a free radical
_--A 1AA11v intermediate (Sliva and O'Brien, 1993). Oxygen-sensitive
chemical reduction of tirapazamine, or other bioreductive
drugs, by endogenous reducing agents such as ascorbate
or reduced glutathione in vivo could provide an extra
degree of tumour selectivity and might show less variation
between tumours than levels of enzymatic reduction.
However, such chemical reduction of tirapazamine under
hypoxia is unlikely to be as important in tumours as in
cell cultures (typically 105-106 cells ml-') as the rate of
cellular metabolism will be greatly enhanced at the much
higher cell densities in vivo (10'-109 cells ml-').
For any bioreductive drug that is selectively toxic towards
hypoxic tumour cells both the level of tumour hypoxia and
the activity of cellular reductases will be important 70 80 determinants of response to that drug. In order to predict
the response of individual tumours to the drug the level of
cic potency of hypoxia and relevant reductase activity could be measured
sensitivity to ssb independently, using oxygen electrodes to assess hypoxia
Le loss; (c), rate (Vaupel et al., 1991) and immunoblot analysis or assaying
I; U, RIF-1; V, for enzyme activity (Workman and Stratford, 1993;
Patterson et al., 1995). However, one of the problems in
applying this enzyme-directed approach to predicting tumour
response to tirapazamine is that it is not clear which
bioreductive enzyme is responsible for activation of the
drug. Although it is widely perceived that cytochrome p450
re possible that reductase is the critical enzyme, and a significant correlation
r metabolism of has been reported between activity of this enzyme and
xicity. Although tirapazamine cytotoxicity in a panel of human breast cancer
)t been unequi- cell lines (Patterson et al., 1995), no correlation was observed
or the metabolic for a panel of human lung tumour lines (Barham et al.,
alently bound to 1995). Even if it was known which enzyme to assay for, it
al., 1995). The would still be necessary to measure the level of hypoxia in
oxicity correlates each tumour. We therefore propose that, for tirapazamine,
similar ratio of the comet assay may be a more promising approach as DNA
e in each of the damage measured using this assay should be a function of
both oxygenation status and enzyme activity. In the present
-tween hypoxic study hypoxic cytotoxicity of tirapazamine correlated with
)f tirapazamine, DNA damage for six human and murine tumour cell lines.
317 and toxicity We are currently exploring further the potential of using this
that metabolism assay to predict the response of tumours to tirapazamine by
s, measured as investigating the relationship between tirapazamine-induced
Dxic cytotoxicity DNA damage and tirapazamine potentiation of tumour cell
on et al., 1995). killing by fractionated radiation.
DNA damage by tirapazamine
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Abbreviatios
2-MEM, alpha minimal essential medium; CHO, Chinese hamster
ovary; dsbs, double-strand breaks; FBS, fetal bovine serum; GSH,
reduced glutathione; PBS, phosphate-buffered saline; s.e., standard
error; s.e.m., standard error of the mean; SF, surviving fraction;
ssbs, single-strand breaks.
Ackuowledgewets
This study was supported by grant CA 15201 from the US
National Cancer Institute. We thank Drs Peggy Olive and Jim
Elwell for helpful discussions and assistance with setting up the
comet assay.
Referenes
BARHAM HM, PATTERSON A, CHINJE EC, HARRIS AL AND
STRATFORD U. (1995). Sensitivity to tirapazamine (SR 4233) is
determined by P450 reductase activity in human breast but not
lung cancer cell lines. Br. J. Cancer, 71 (Supp. XXIV), 20.
BIEDERMANN KA, WANG J, GRAHAM RP AND BROWN JM. (1991).
SR 4233 cytotoxicity and metabolism in DNA repair-competent
and repair-deficient cell cultures. Br. J. Cancer, 63, 358-362.
BROWN JM. (1993). SR 4233 (tirapazamine): a new anticancer drug
exploiting hypoxia in solid tumours. Br. J. Cancer, 67, 1163-
1170.
BROWN JM AND GIACCIA AJ. (1994). Tumour hypoxia: the picture
has changed in the 1990s. Int. J. Radiat. Biol., 65, 95-102.
BROWN JM AND KOONG A. (1991). Therapeutic advantage of
hypoxic cells in tumors: A theoretical study. J. Natl Cancer Inst.,
83, 178-185.
BROWN JM AND LEMMON MJ. (1990). Potentiation by the hypoxic
cytotoxin SR 4233 of cell killing produced by fractionated
irradiation ofmouse tumors. Cancer Res., 50, 7745-7749.
BROWN JM AND LEMMON MJ. (1991). Tumor hypoxia can be
exploited to preferentially sensitize tumors to fractionated
irradiation. Int. J. Radiat. Oncol. Biol. Phys., 20, 457-461.
BUSH RS, JENKIN RDT, ALLT WEC, BEALE FA, BEAN H, DENBO AJ
AND PRINGLE JF. (1978). Definitive evidence for hypoxic cells
influencing cure in cancer therapy. Br. J. Cancer, 37 (Suppl. III),
302-306.
COLE S, STRATFORD U, FIELDEN EM, ADAMS GE, LEOPOLD W,
ELLIOTT W, SUTO M AND SEBOLT-LEOPOLD J. (1992). Dual
function nitroimidazoles less toxic than RSU 1069: selection of
candidate drugs for clinical trial (RB 6145 and/or PD 130908).
Int. J. Radiat. Oncol. Biol. Phys., 22, 545-548.
DENNY WA AND WILSON WR. (1993). Bioreducible mustards: a
paradigm for hypoxia-selective prodrugs of diffrusible cytotoxins
(HPDCs). Cancer Metastasis Rev., 12, 135- 151.
DOHERTY N, HANCOCK SL, KAYE S, COLEMAN CN, SHULMAN L,
MARQUEZ C, MARISCAL C, RAMPLING R, SENAN S AND
ROEMELING RV. (1994). Muscle cramping in phase I clinical
trials oftirapazamine (SR 4233) with and without radiation. Int.
J. Radiat. Oncol. Biol. Phys., 29, 379-382.
DORIE MJ AND BROWN JM. (1993). Tumor-specific, schedule-
dependent interaction between tirapazamine (SR 4233) and
cisplatin. Cancer Res., 53, 4633-4636.
DURAND RE. (1994). The influence of microenviroumental factors
during cancer therapy. In vivo, 8, 691 -702.
GATENBY RA, KESSLER HB, ROSENBLUM JS, COIA LR, MOLDOF-
SKY PJ, HARTZ WH AND BRODLER GJ. (1988). Oxygen
distribution in squamous cell carcinoma metastases and its
relationship to outcome of radiation therapy. Int. J. Radiat.
Oncol. Biol. Phys., 14, 831-838.
HIRST DG, BROWN JM AND HAZLEHURST JL. (1983). Effect of
partition coefficient on the ability of nitroimidazoles to enhance
the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea.
Cancer Res., 43, 1961-1965.
HOCKEL M, SCHLENGER K, KNOOP C AND VAUPEL P. (1991).
Oxygenation of carcinomas of the uterine cervix: Evaluation by
computerized 02 tension measurements. Cancer Res., 51, 6098-
6102.
HOCKEL M, KNOOP C, SCHLENGER K, VORNDRAN B, BAUBMANN
E, MITZE M, KNAPSTEIN PG AND VAUPEL P. (1993).
Intratumoral PO2 predicts survival in advanced cancer of the
uterine cervix. Radiother. Oncol., 26, 45-50.
HUGHES CS, SHEN JW AND SUBJECK JR. (1989). Resistance to
etoposide induced by three glucose-regulated stresses in Chinese
hamster ovary cells. Cancer Res., 49, 4452-4454.
KIM IH AND BROWN JM. (1994). Reoxygenation and rehypoxiation
in the SCCVII mouse tumor. Int. J. Radiat. Oncol. Biol. Phys., 29,
493-497.
KOCH Cl. (1993). Unusual oxygen concentration dependence of
toxicity ofSR-4233, a hypoxic cell toxin. Cancer Res., 53, 3992-
3997.
MARSHALL RS AND RAUTH AM. (1986). Modification of the
cytotoxic activity ofmitomycin C by oxygen and ascorbic acid in
Chinese hamster ovary cells and a repair-deficient mutant. Cancer
Res., 46, 2709-2713.
MARSHALL RS AND RAUTH AM. (1988). Oxygen and exposure
kinetics as factors influencing the cytotoxicity ofporfiromycin, a
mitomycin C analogue, in Chinese hamster ovary cells. Cancer
Res., 48, 5655-5659.
MOSELENJW,HAYMP, DENNYWAANDWILSONWR. (1995). N-[2-
(2-methyl-5-nitroimidazolyl) ethyl}4-(2-nitroimidazolyl) butana-
mide (NNB, NSC 639862), a bis-nitroimidazole with enhanced
selectivity as a bioreductive drug. Cancer Res., 55, 574-580.
MUELLER-KLEISER W, SCHLENGER KH, WALENTA S, GROSS M,
KARBACH U, HOECKEL M AND VAUPEL P. (1991). Pathophy-
siological approaches to identifying tumor hypoxia in patients.
Radiother. Oncol., 1, 21-28.
OLIVE PL. (1995a). Detection of hypoxia by measurement of DNA
damage in individual cells from spheroids and murine tumours
exposed to bioreductive drugs. I. Tirapazamine. Br. J. Cancer, 71,
529-536.
OLIVE PL. (1995b). Detection of hypoxia by measurement of DNA
damage in individual cells from spheroids and murine tumours
exposed to bioreductive drugs. II. RSU 1069. Br. J. Cancer, 71,
537-542.
OLIVE PL AND DURAND RE. (1992). Detection ofhypoxic cells in a
murine tumor with the use of the Comet Assay. J. Natl Cancer
Inst., 84, 707-71 1.
OLIVE PL, BANATH JP AND DURAND RE. (1990). Heterogeneity in
radiation-induced DNA damage and repair in tumor and normal
cells measured using the 'comet' assay. Radiat. Res., 122, 86-94.
OLIVE PL, WLODEK D AND BANATH JP. (1991). DNA double-
strand breaks measured in individual cells subjected to gel
electrophoresis. Cancer Res., 51, 4671-4676.
OLIVE PL, WLODEK D, DURAND RE AND BANATH JP. (1992).
Factors influencing DNA migration from individual cells
subjected to gel electrophoresis. Exp. Cell Res., 198, 259-267.
OLIVE PL, DURAND RE, LE RICHE J, OLIVOTTO IA AND JACKSON
SM. (1993a). Gel electrophoresis of individual cells to quantify
hypoxic fraction in human breast cancers. Cancer Res., 53, 733-
736.
OLIVE PL, FRAZER G AND BANATH JP. (1993b). Radiation-induced
apoptosis measured in TK6 human B lymphoblast cells using the
comet assay. Radiat Res., 136, 130-136.
OSTLING 0 ANDJOHANSON KJ. (1984). Microelectrophoretic study
of radiation-induced DNA damages in individual mammalian
cells. Biochem. Biophys. Res. Commwu., 123, 291-298.
PATTERSON AV, BARHAM HM, CHINJE EC, ADAMS GE, HARRIS
AL AND STRATFORD U. Importance ofP450 reductase activity in
determining sensitivity of breast tumor cells to the bioreductive
drug tirapazamine (SR 4233). Br. J. Cancer, 72, 1144-1150.
PLUMB JA, GERRITSEN M AND WORKMAN P. (1994). DT-
diaphorase protects cells from the hypoxic cytotoxicity of the
indoloquinone E09. Br. J. Cancer, 70, 1136- 1143.
ROBERTSON N, HAIGH A, ADAMS GE AND STRATFORD IJ. (1994).
Factors affecting sensitivity to E09 in rodent and human tumour
cells in vitro: DT-diaphorase activity and hypoxia. Eur. J. Cancer,
30A, 1013-1019.
ROCKWELL SC, KALLMAN RF AND FAJARDO LF. (1972).
Characteristics ofa serially transplanted mouse mammary tumor
and its tissue-culture-adapted derivative. J. Natl Cancer Inst., 49,
735-749.
SEBOLT-LEOPOLD JS, ELLIOT WL, SHOWALTER HD AND LEO-
POLD WR. (1993). Rationale for selection of PD 144872, the R
isomer of RB 6145, for clinical development as a radiosensitizer.
Proc. Am. Assoc. Cancer Res., 34, 362.
SIIM BG, ATWELL GJ ANDWILSON WR. (1994). Oxygen dependence
of the cytotoxicity and metabolic activation of 4-alkylamino-5-
nitroquinoline bioreductive drugs. Br. J. Cancer, 70, 596-603.DNA dunag. by t*opaza*ie
BG Su et a
960
SILVA JM AND O'BRIEN PJ. (1993). Molecular mechanisms of SR
4233-induced hepatocyte toxicity under aerobic versus hypoxic
conditions. Br. J. Cancer, 68, 484-491.
STRATFORD IU ANDSTEPHENS MA. (1989). Thedifferential hypoxic
cytotoxicity of bioreductive agents determined in vitro by the
MTT assay. Int. J. Radiat. Oncol. Biol. Phys., 16, 973-976.
STRATFORD IJ, O'NEILL P, SHELDON PW, SILVER ARJ AND
WALLING JM. (1986). RSU 1069, a nitroimidazole compound
containing an aziridine group. Bioreduction greatly increases
cytotoxicity under hypoxic conditions. Biochem. Pharmacol., 35,
105-109.
TANNOCK IF. (1978). Cell kinetics and chemotherapy: A critical
review. Cancer Treat. Rep., 62, 1117-1133.
TWENTYMAN PR, BROWN JM, GRAY JW, FRANKO AJ, SCOLES MA
AND KALLMAN RF. (1980). A new mouse tumor model system
(RIF-1) forcomparison ofend-point studies. J. Natl Cancer Inst.,
64, 595-604.
VAUPEL P, SCHLENGER K, KNOOP C AND HOCKEL M. (1991).
Oxygenation of human tumors: evaluation of tissue oxygen
distribution in breast cancers by computerized 02 tension
measurements. Cancer Res., 51, 3316-3322.
WANG J, BIEDERMANN KA AND BROWN JM. (1992). Repair of
DNA and chromosome breaks in cells exposed to SR 4233 under
hypoxia or to ionizing radiation. Cancer Res., 52, 4473-4477.
WILSON WR AND DENNY WA. (1992). DNA-binding nitrohetero-
cycles as hypoxia-selective cytotoxins. In Radiation Research: A
Twentieth-Century Perspective, Dewey WC, Edington M, Fry
RJM, Hall EJ and Whitmore GF (eds) pp. 796-801. Academic
Press: New York.
WORKMAN P AND STRATFORD U. (1993). The experimental
development of bioreductive drugs and their role in cancer
therapy. Cancer Metastasis Rev., 12, 73-82.
ZEMAN EM AND BROWN JM. (1989). Pre- and post-irradiation
radiosensitization by SR 4233. Int. J. Radiat. Oncol. Biol. Phys.,
16, 967-971.
ZEMAN EM, BROWN JM, LEMMON MJ, HIRST VK AND LEE WW.
(1986). SR-4233: a new bioreductive agent with high selective
toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol.
Phys., 12, 1239- 1242.
ZEMAN EM, HLRST VK, LEMMON MJ AND BROWN JM. (1988).
Enhancement of radiation-induced tumor cell killing by the
hypoxic cell toxin SR 4233. Radiother. Oncol., 12, 209-218.
ZHANG H, KOCH a, WALLEN CA AND WHEELER KT. (1995).
Radiation-induced DNA damage in tumors and normal tissues.
III. Oxygen dependence of the formation of strand breaks and
DNA-protein crosslinks. Radiat. Res., 142, 163- 168.